Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Use of Modified Peptide Nucleic Acids for Visualizing DNA

Posted Mar 24 2010 5:00pm

Description of Invention:
The compounds described in this technology may be useful in the development of nucleic acid detection kits for various pathogens.

Technologies for genomic detection most commonly use DNA probes to hybridize to target sequences, and require the use of Polymerase Chain Reaction (PCR) to amplify target sequences. Replacing the DNA probe with peptide nucleic acid (PNA) can greatly eliminate the need for PCR because the binding strength of PNAs to complementary DNA is stronger than DNA binding to complementary DNA. In addition, PNAs are nuclease and protease resistant, and form very stable and highly sequence-specific complexes with DNA.

This technology describes a method of making pure enantiomers of trans-tert-butyl-2-aminocyclopentylcarbamate (tcycp) and methods of modifying PNAs by incorporating tcycp compounds into the PNA. This technology may also be practical for detecting infectious agents such as anthrax, avian flu, tuberculosis (TB), severe acute respiratory syndrome (SARS), human papilloma virus (HPV) and human immunodeficiency virus (HIV).

Applications:
  • Very stable diagnostic method to detect nucleic acids without using Polymerase Chain Reaction (PCR)
  • Binding to complementary DNA can be seen by eye
  • Visual detection of anthrax has been shown
  • Useful for outside of a laboratory environment


Development Status:
Early stage

Inventors:
Daniel Appella (NIDDK)


Patent Status:
HHS, Reference No. E-308-2006/2
US, Application No. 12/441,925 filed 19 Mar 2009


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic Chemistry, Drug-Receptor Interactions Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Dr. Daniel Appella at appellad@niddk.nih.gov for more information.


Portfolios:
Nanotechnology



For Additional Information Please Contact:
Charlene Sydnor Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: sydnorc@mail.nih.gov
Phone: 301-435-4689
Fax: 301-402-0220


Ref No: 2093

Updated: 03/2010

Post a comment
Write a comment:

Related Searches